Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SENP3-EIF4A1 readthrough (NMD candidate) (SENP3-EIF4A1)
- Target
- SENP3-EIF4A1
- Molecular classification
- Long non-coding RNA (lncRNA), Readthrough transcript, Chimeric RNA (fusion gene product)
01
Overview
SENP3-EIF4A1 is a long non-coding RNA formed by readthrough transcription or a fusion event between the SUMO-specific peptidase 3 (SENP3) and Eukaryotic translation initiation factor 4A1 (EIF4A1) genes located on chromosome 17. This transcript is typically targeted for nonsense-mediated decay and does not encode a functional protein. Recent research implicates SENP3-EIF4A1 as a competing endogenous RNA (ceRNA) in triple-negative breast cancer, where it acts as a sponge for miR-195-5p and regulates expression of Cyclin E1 (CCNE1), thereby promoting cell proliferation and cancer progression. Its expression correlates with poor prognosis in TNBC. The molecule is being investigated as a potential diagnostic biomarker and therapeutic target, especially as part of the SENP3-EIF4A1/miR-195-5p/CCNE1 axis, but its full biological function and disease spectrum remain incompletely characterized.
- Other names
- SENP3-EIF4A1SENP3-EIF4A1 readthroughSENP3-EIF4A1 fusion transcript
02
Mechanism of action
For 5-Aza-DC: Demethylation leads to upregulation of miR-195-5p, which downregulates CCNE1 expression, disrupting the oncogenic SENP3-EIF4A1/miR-195-5p/CCNE1 axis
03
Biological functions
Competing endogenous RNA (ceRNA) or microRNA spongeRegulation of gene expressionModulation of cell proliferation and cell cycle via downstream targets
04
Disease associations
Cancer, particularly triple-negative breast cancer (TNBC)Potential implication in other malignancies (limited direct evidence)
05
Safety considerations
As a non-coding RNA target, there may be challenges in specificity and off-target effects for oligonucleotide or RNA-based therapiesThe functional relevance is incompletely understood, increasing risk of unintended consequences
06
Interacting drugs
5-Aza-2'-deoxycytidine (5-Aza-DC)
07
Biomarkers
Elevated SENP3-EIF4A1 expression as prognostic indicator for poor outcome in TNBCRelated axis biomarkers: miR-195-5p, CCNE1 expression
Beyond the preview
Go deeper on SENP3-EIF4A1 readthrough (NMD candidate) (SENP3-EIF4A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SENP3-EIF4A1 readthrough (NMD candidate) (SENP3-EIF4A1).